386 related articles for article (PubMed ID: 17434555)
21. Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.
Shirakawa K; Takaori-Kondo A; Kobayashi M; Tomonaga M; Izumi T; Fukunaga K; Sasada A; Abudu A; Miyauchi Y; Akari H; Iwai K; Uchiyama T
Virology; 2006 Jan; 344(2):263-6. PubMed ID: 16303161
[TBL] [Abstract][Full Text] [Related]
22. APOBEC-mediated editing of viral RNA.
Bishop KN; Holmes RK; Sheehy AM; Malim MH
Science; 2004 Jul; 305(5684):645. PubMed ID: 15286366
[TBL] [Abstract][Full Text] [Related]
23. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.
Bogerd HP; Tallmadge RL; Oaks JL; Carpenter S; Cullen BR
J Virol; 2008 Dec; 82(23):11889-901. PubMed ID: 18818324
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3G targets human T-cell leukemia virus type 1.
Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
[TBL] [Abstract][Full Text] [Related]
25. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.
Huthoff H; Autore F; Gallois-Montbrun S; Fraternali F; Malim MH
PLoS Pathog; 2009 Mar; 5(3):e1000330. PubMed ID: 19266078
[TBL] [Abstract][Full Text] [Related]
26. Multifaceted antiviral actions of APOBEC3 cytidine deaminases.
Chiu YL; Greene WC
Trends Immunol; 2006 Jun; 27(6):291-7. PubMed ID: 16678488
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins.
Wiegand HL; Cullen BR
J Virol; 2007 Dec; 81(24):13694-9. PubMed ID: 17913830
[TBL] [Abstract][Full Text] [Related]
28. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
Schäfer A; Bogerd HP; Cullen BR
Virology; 2004 Oct; 328(2):163-8. PubMed ID: 15464836
[TBL] [Abstract][Full Text] [Related]
29. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H.
Soros VB; Yonemoto W; Greene WC
PLoS Pathog; 2007 Feb; 3(2):e15. PubMed ID: 17291161
[TBL] [Abstract][Full Text] [Related]
30. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
31. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
32. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.
Mahieux R; Suspène R; Delebecque F; Henry M; Schwartz O; Wain-Hobson S; Vartanian JP
J Gen Virol; 2005 Sep; 86(Pt 9):2489-2494. PubMed ID: 16099907
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
Rose KM; Marin M; Kozak SL; Kabat D
J Biol Chem; 2004 Oct; 279(40):41744-9. PubMed ID: 15297452
[TBL] [Abstract][Full Text] [Related]
34. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
[TBL] [Abstract][Full Text] [Related]
35. Complementary function of the two catalytic domains of APOBEC3G.
Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
[TBL] [Abstract][Full Text] [Related]
36. Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition.
Bulliard Y; Turelli P; Röhrig UF; Zoete V; Mangeat B; Michielin O; Trono D
J Virol; 2009 Dec; 83(23):12611-21. PubMed ID: 19776130
[TBL] [Abstract][Full Text] [Related]
37. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
[TBL] [Abstract][Full Text] [Related]
38. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
Bonvin M; Achermann F; Greeve I; Stroka D; Keogh A; Inderbitzin D; Candinas D; Sommer P; Wain-Hobson S; Vartanian JP; Greeve J
Hepatology; 2006 Jun; 43(6):1364-74. PubMed ID: 16729314
[TBL] [Abstract][Full Text] [Related]
39. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
Russell RA; Wiegand HL; Moore MD; Schäfer A; McClure MO; Cullen BR
J Virol; 2005 Jul; 79(14):8724-31. PubMed ID: 15994766
[TBL] [Abstract][Full Text] [Related]
40. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
Wang T; Zhang W; Tian C; Liu B; Yu Y; Ding L; Spearman P; Yu XF
Virology; 2008 Jul; 377(1):71-9. PubMed ID: 18495196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
